OctoPlus N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
23 feb 2011 - 21:31
Statutaire naam
OctoPlus N.V.
Titel
OctoPlus expands development agreement with ESBATech on controlled release product for ophthalmic indications
Bericht
OctoPlus N.V. (“OctoPlus” or the “Company”) (Euronext: OCTO) announces today that it has signed a contract with ESBATech, an Alcon Biomedical Research Unit, to develop a controlled release formulation for one of its proprietary biological compounds for ophthalmic applications.
The project includes process development, scale-up and manufacturing for pre-clinical studies. Financial details are not disclosed, but the project will make a material contribution to our annual revenues in 2011. In addition to Locteron®, this programme will be part of our portfolio of projects utilising our proprietary technologies.
Datum laatste update: 15 maart 2026